NCT06373458View on ClinicalTrials.gov

Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy

PHASE2RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Keloid

Interventions

DRUG

Ritlecitinib

Ritlecitinib 50mg QD for 36 weeks starting at Day 1

Trial Locations (1)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER